| P/E (FY) | — | Sales (TTM) | $50,000 |
| Earnings (TTM) | -$41.6M | ROE | −165.16% |
| Net Margin | −91866.00% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −48.87% |
| Market Cap | $45.5M | Trading Days | 1875 |
| 52W High | 3.24 |
| 52W Low | 1.09 |
| % Off High | −47.29% |
| YTD | 9.62% | 1Y | −41.24% |
| 3Y | −79.72% | 5Y | −90.47% |
| Since incept. (ann.) | −18.63% |
| Ann. Volatility (1Y) | 76.00% | Ann. Volatility (3Y) | 87.30% |
| Sharpe (1Y) | −0.34 | Sharpe (3Y) | −0.14 |
| Max Drawdown (1Y) | −64.56% | Max Drawdown (3Y) | −92.01% |
| Beta (3Y, vs SPY) | 0.91 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MGX | Metagenomi Therapeutics, Inc. | $45.6M | — |
| ATYR | aTYR PHARMA INC | $48.4M | — |
| ELUT | ELUTIA INC. | $42.0M | 1.1 |
| TIL | Instil Bio, Inc. | $49.4M | — |
| INKT | MiNK Therapeutics, Inc. | $52.5M | — |
| DYAI | DYADIC INTERNATIONAL INC | $38.6M | — |
| EXOZ | EXOZYMES INC. | $37.3M | — |
| CRDF | Cardiff Oncology, Inc. | $55.9M | — |
| SCLX | Scilex Holding Co | $57.9M | — |
| ESLA | Estrella Immunopharma, Inc. | $32.2M | — |
| LONA | LeonaBio, Inc. | $65.5M | — |
| ATRA |
| Atara Biotherapeutics, Inc. |
| $70.4M |
| 3.0 |
